

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/094066 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 40/11 (2025.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/IB2024/060685

(22) International Filing Date:

30 October 2024 (30.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/546,612	31 October 2023 (31.10.2023)	US
63/607,655	08 December 2023 (08.12.2023)	US
63/650,457	22 May 2024 (22.05.2024)	US

(71) Applicant: CELLENKOS, INC. [US/US]; 5416 Chaucer Drive, Houston, Texas 77005 (US).

(72) Inventor: PARMAR, Simrit; 5122 Morningside Drive, Apt. 1025, Houston, Texas 77005 (US).


(74) Agent: PAVAO, Matthew et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: USES OF REGULATORY T CELLS FOR TREATING MYELOFIBROSIS

FIG. 1



(57) Abstract: Provided herein are medical uses of CXCR4-enriched T regulatory cells in combination with ruxolitinib for treating myelofibrosis or ameliorating a symptom of myelofibrosis in subjects with poor response to ruxolitinib monotherapy.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*